STAT3 and non-small cell lung carcinoma: MAPK signaling primarily targets JUN that subsequently cooperates with STAT3 upregulating PD-L1 expression in BRAF inhibition (BRAFi)-resistant melanoma and NSCLC, where the signaling cascade is reversible by MEK inhibition (MEKi) [58, 59].